Spratlin Jennifer L, Mulder Karen E
Department of Oncology, Cross Cancer Institute, School of Cancer, Imaging and Engineering Sciences, Faculty of Medicine and Dentistry, University of Alberta, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.
Int J Mol Sci. 2011;12(9):5895-907. doi: 10.3390/ijms12095895. Epub 2011 Sep 14.
The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.
胰腺癌的发病率和死亡率趋于一致。自吉西他滨被接受为标准治疗方法以来，胰腺癌的治疗进展甚微。不幸的是，吉西他滨的疗效不佳。虽然关于开发生物标志物以指导该领域治疗的讨论很多，但将其应用于临床实践的行动却很少。在此，我们综述了潜在的胰腺癌生物标志物，并讨论了其应用中的局限性。
